1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

PDUFA VII Communications: Earlier PMR Talks, Formal Meeting Additions

 
• By Derrick Gingery

Sponsors will receive additional agency interactions through the formal meeting process, as well as an option to ask clarifying questions later.

Turning clock back
During PDUFA VII, sponsors should learn earlier in the assessment period that a postmarketing requirement may be necessary. • Source: Alamy

Most new drug applicants will receive an earlier warning that postmarketing requirements are necessary upon approval during the next prescription drug user fee program cycle.

A common industry complaint is that often postmarket requirements (PMRs) are hurriedly agreed to at the end of an application assessment, even though they may not

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

US FDA User Fee Collection Safe In Preliminary Trump 2026 Budget Plan

 
• By Cathy Kelly

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.

Updated: US Likely To Lose Its First Approver Advantage After FDA Layoffs

 
• By Sarah Karlin-Smith, Elizabeth Orr, and Derrick Gingery

Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.

‘Pipeline In A Pill’ Or Pipe Dream? US FDA’s April Goal Dates Test Expansion Strategies

 
• By Bridget Silverman

Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.

More from Pathways & Standards